The Clinical Usefulness of Biochemical Markers of Bone Formation in Patients with Multiple Myeloma.
- Author:
Young Uk CHO
1
;
Won Ki MIN
;
Chan Jeoung PARK
;
Hyun Sook CHI
Author Information
1. Department of Laboratory Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea. hschi@amc.seoul.kr
- Publication Type:Original Article
- Keywords:
Multiple myeloma;
Bone-specific alkaline phosphatase;
Osteocalcin
- MeSH:
Alkaline Phosphatase;
Biomarkers*;
Bone Resorption;
Creatinine;
Hand;
Humans;
Leukemia, Plasma Cell;
Monoclonal Gammopathy of Undetermined Significance;
Multiple Myeloma*;
Osteocalcin;
Osteogenesis*;
Tumor Burden
- From:The Korean Journal of Laboratory Medicine
2005;25(5):285-289
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Bone lesions in multiple myeloma (MM) are related to an uncoupling of bone resorption and formation. This study was to evaluate the potential clinical value of biochemical markers of bone formation in patients with MM. METHODS: Serum bone-specific alkaline phosphatase (BAP) and osteocalcin (OC) were measured in 217 sera from 77 patients with MM, 1 patient with plasma cell leukemia, and 12 patients with monoclonal gammopathy of undetermined significance (MGUS); 30 age- and sex-matched controls were also enrolled. RESULTS: Serum OC, but not serum BAP, was lower in MM and MGUS patients than in controls. Serum BAP decreased significantly as the tumor burden increased (P=0.035), but serum OC did not decrease. On the other hand, serum OC increased significantly in patients in an advanced stage according to the new international staging system (P=0.036), whereas serum BAP did not exhibit such a change. Serum OC and BAP showed positive correlations with albumin; serum OC also showed positive correlations with beta2-microglobulin and creatinine. CONCLUSIONS: Serum BAP, rather than serum OC, appears to be helpful in monitoring MM. The clinical usefulness of serum BAP may be enhanced in MM patients with renal impairment.